查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014387

重症医学市场：2026-2032年全球市场预测（按产品类型、给药途径、患者族群、治疗应用和最终用户划分）

Critical Care Therapeutics Market by Product Type, Administration Routes, Patient Demographics, Therapeutic Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年重症监护药物市场价值 14.8 亿美元，预计到 2026 年将成长至 15.7 亿美元，复合年增长率为 5.66%，到 ​​2032 年将达到 21.8 亿美元。

主要市场统计数据
基准年 2025 14.8亿美元
预计年份：2026年 15.7亿美元
预测年份 2032 21.8亿美元
复合年增长率 (%) 5.66%

全面概述了影响重症监护医学未来的临床重点、营运压力和战略意义。

目前重症监护正处于战略十字路口，临床需求、技术进步和政策趋势在此交汇。医疗系统和采购领导者面临着建立更具韧性的供应链、采用循证疗法和医疗设备以及使资金配置与新兴临床重点保持一致的压力。本导言旨在为后续分析提供框架，引导读者了解影响急性照护环境中临床实践、医疗设备使用和治疗方法选择的各种因素。

监测、治疗方法和基于价值的奖励方面的创新如何重塑重症监护的临床路径和价值链优先事项。

过去几年，监测、药理学和系统韧性方面的进步共同重塑了重症监护的模式。远端监测设备和封闭回路型输液系统已从原型阶段过渡到临床应用，改变了床边护理的节奏，并能够更早发现生理衰退。同时，人们越来越关注透过药物优化（特别是镇静策略和神经肌肉阻断剂）来缩短人工呼吸器时间和减少相关併发症的方案。

本研究评估了 2025 年美国关税措施对营运和采购的影响，以及这些措施如何改变了采购、价格弹性和临床连续性。

美国2025年实施的关税措施的累积影响，在采购、製造和临床运营的各个领域都造成了显着的摩擦，促使整个价值链即时采取战略应对措施。关税导致投入成本增加，迫使製造商和经销商重新评估其人工呼吸器、监护设备、注射器以及某些活性药物成分关键组件的筹资策略。在许多情况下，供应商在短期内承担了边际成本，但关税的长期影响迫使他们与医疗系统重新谈判价格，并重新协商商业合约。

从产品、给药途径、患者人口统计、治疗用途和医疗保健环境的角度，确定临床、采购和创新重点，并以细分观点主导。

精准的细分观点阐明了临床需求、采购优先顺序和创新如何在产品类型、给药途径、患者族群、治疗应用和终端使用者环境等因素之间相互交织。基于产品类型，重点在于植入式医疗设备、静脉输液袋、药品、监测设备、注射器和导管以及人工呼吸器。药品进一步细分为抗生素、神经肌肉阻断剂、镇静剂和血栓溶解剂，以反映不同的临床方案和供应途径。基于给药途径，吸入、静脉注射和口服给药各有不同的性能特征和普及率，每种给药途径在监管、储存和给药方面也面临不同的挑战，从而影响采购和床边工作流程。

决定美洲、欧洲、中东和非洲以及亚太地区临床引入、监管准入和供应链韧性的区域策略趋势。

区域趋势持续影响着美洲、欧洲、中东和非洲（EMEA）以及亚太地区的临床应用、监管时间表和供应商企业发展，每个地区都为製造商和医疗服务提供者带来了独特的优势和挑战。在美洲，完善的报销机制和一体化的医院系统为循证技术创造了有利环境，这些技术能够显着缩短住院时间和减少併发症；然而，这些市场面临着严格的检验审查和竞争性竞标，尤其註重已验证的临床结果。

市场领导之间的竞争行为和策略挑战，结合产品整合、证据产生和供应链强化。

主要企业之间的竞争动态反映了双重需求：既要维持营运韧性，又要加速临床差异化。为了获得可持续的竞争优势，企业正致力于投资整合医疗设备和分析能力、完善的上市后监测以及能够保障持续收入的耗材生态系统的整合解决方案。许多领导企业正在推行模组化平台策略，实现分阶段升级而无需彻底更换，从而减轻医院资本投资负责人的负担，并促进临床环境中的平稳过渡。

产业领导者可以采取哪些优先可行的步骤来增强供应链韧性、临床部署和实证差异化？

产业领导企业应优先采取一系列高影响力行动，将洞察转化为可衡量的改进，从而提升产品的可用性、临床性能和商业性竞争力。首先，透过投资互通性标准和以临床医生为中心的设计，使产品路线蓝图与临床工作流程保持一致。这可以降低采用门槛，并提高新型监测和呼吸器技术成为标准实践的可能性。其次，实现製造地和供应商基础的多元化，以降低关税风险和物流中断的影响。在采购合约中加入近岸外包和多源采购条款，以确保在面对地缘政治或贸易变化时业务永续营运。

一种透明的、基于三角测量的调查方法，结合了初步临床访谈、系统性的二次检验和情境测试，以支援策略决策。

本分析所采用的研究途径结合了结构化的初步研究和系统的二次检验，以确保结论是基于证据且具有实际意义。初步研究包括对急诊护理机构的临床负责人、采购负责人和供应链主管进行访谈，从而获得关于设备可用性、治疗方法选择和库存管理实践的第一手观点。这些定性研究结果与产品生命週期文件、监管申报文件和公开的临床试验报告进行交叉比对，以检验设备推广应用的驱动因素和风险因素。

策略结论强调互通性、采购韧性和实证方案是改善结果和实现可持续竞争优势的途径。

总之，在临床创新、健全的采购体系和日益增长的地缘政治敏感性的驱动下，重症监护医疗设备正在经历一场结构性变革。对更佳治疗效果的需求、更严格的采购审查以及政策驱动的贸易中断等多重压力，迫使各企业在产品设计、供应链建构和实证实践方面做出调整。那些能够将与临床工作流程的兼容性、健全的采购体係以及有针对性的真实世界检验相结合的企业，将为产品推广铺平道路，并确立强大的市场地位。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：重症监护药物市场：依产品类型划分

  • 植入式医疗设备
  • 静脉输液袋
  • 製药
    • 抗生素
    • 神经肌肉阻断剂
    • 镇静剂
    • 溶栓剂
  • 监控设备
  • 注射器和导管
  • 人工呼吸器

第九章：重症监护药物市场依给药途径划分

  • 吸入
  • 静脉
  • 口服

第十章：依病患细分分類的重症监护药物市场

  • 成年患者
  • 老年患者
  • 新生儿加护病房（NICU）
  • 儿童患者

第十一章：按治疗应用分類的重症监护药物市场

  • 循环系统护理
  • 紧急復苏
  • 神经系统疾病
    • 颅内压监测
    • 创伤性脑损伤
  • 肾臟替代疗法
  • 呼吸护理
    • 气喘
    • 慢性阻塞性肺病
    • 肺水肿

第十二章 重症监护药物市场：依最终用户划分

  • 门诊手术中心
  • 居家医疗
  • 医院
  • 长期照护机构

第十三章：重症监护药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 重症监护药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 重症监护药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国重症监护药物市场

第十七章：中国重症监护药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd. by Sartorius AG
  • Aspen Group
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio Products Laboratory Ltd.
  • Collegium Pharmaceutical, Inc.
  • CSL Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Grifols SA
  • Johnson & Johnson
  • Kedrion Spa
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Shanghai RAAS
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4311CE1A33EE

The Critical Care Therapeutics Market was valued at USD 1.48 billion in 2025 and is projected to grow to USD 1.57 billion in 2026, with a CAGR of 5.66%, reaching USD 2.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.48 billion
Estimated Year [2026] USD 1.57 billion
Forecast Year [2032] USD 2.18 billion
CAGR (%) 5.66%

An integrative overview that frames clinical priorities, operational pressures, and strategic implications shaping the future of critical care therapeutics

The critical care therapeutics landscape sits at a strategic crossroads where clinical imperative, technological advancement, and policy dynamics converge. Health systems and procurement leaders face pressure to integrate more resilient supply chains, adopt evidence-driven therapeutics and devices, and align capital allocation with emerging clinical priorities. This introduction frames the analysis that follows by situating the reader within the broader forces shaping clinical practice, device utilization, and therapeutic selection across acute care settings.

This report synthesizes regulatory developments, clinical innovation, and operational stressors that together reshape how critical care is delivered. Readers should expect concise, actionable insight that bridges clinical need with commercial strategy, helping manufacturers, providers, and payers prepare for accelerating demand for integrated monitoring solutions, advanced ventilatory support, and targeted medication protocols. By grounding the discussion in real-world drivers rather than speculative projections, the introduction sets the tone for a pragmatic review focused on adoption barriers, supply dynamics, and strategic opportunities.

How innovations in monitoring, therapeutics, and value-based incentives are remapping clinical pathways and supply chain priorities in critical care

Over the past several years, transformative shifts have reconfigured the critical care landscape, driven by converging advances in monitoring, pharmacology, and systems resilience. Remote-capable monitoring devices and closed-loop infusion systems have migrated from prototype to clinical deployment, changing the cadence of bedside management and enabling earlier detection of physiologic decline. At the same time, pharmacologic optimization-particularly in sedation strategies and neuromuscular blockade-has sharpened focus on protocols that reduce ventilation time and downstream complications.

Payment reforms and value-based purchasing models have further incentivized reductions in length of stay and readmission rates, prompting hospitals to adopt technologies and therapeutics that demonstrably improve throughput and patient outcomes. Parallel to these clinical and economic drivers, capital flows have increasingly favored integrated solutions that combine device telemetry, analytics, and consumable therapies, accelerating partnership models between device makers and software providers. The combined effect is an ecosystem that rewards interoperability, evidence of clinical benefit, and supply chain transparency, shifting competitive advantage toward organizations that can deliver end-to-end clinical value.

Assessing the operational and procurement consequences of the 2025 US tariff measures and how they reshaped sourcing, pricing resilience, and clinical continuity

The cumulative impact of the United States tariffs implemented in 2025 introduced material frictions across procurement, manufacturing, and clinical operations, prompting immediate strategic responses across the value chain. Tariff-driven input cost inflation has required manufacturers and distributors to reassess sourcing strategies for key components used in ventilators, monitoring devices, syringes, and certain active pharmaceutical ingredients. In many instances, suppliers absorbed marginal costs short term, but persistent tariff exposure has forced price renegotiation and commercial re-contracting with health systems.

Clinicians and hospital supply teams responded by prioritizing suppliers with diversified production bases and clearer contingency planning, while purchasing departments accelerated qualification of alternate vendors to avoid single-source vulnerability. Where tariffs intersected with regulatory requirements for specific device specifications or medication formulations, lead times extended as manufacturers worked to relocate production or certify new facilities. The net operational consequence was an increased emphasis on inventory buffer strategies, tighter coordination between clinical and procurement teams, and contractual clauses that transfer or mitigate tariff risk. Looking forward, organizations that institutionalize dynamic sourcing, nearshoring, and transparent landed-cost modeling will navigate tariff disruptions more effectively and protect continuity of critical care delivery.

Segment-driven perspectives that pinpoint clinical, procurement, and innovation priorities across products, routes, demographics, therapeutic use cases, and care settings

A nuanced segmentation lens clarifies where clinical demand, procurement priority, and innovation converge across product types, administration routes, patient demographics, therapeutic applications, and end-user environments. Based on product type, attention concentrates on implantable devices, intravenous infusion bags, medications, monitoring devices, syringes & catheters, and ventilators, with medications further differentiated by antibiotics, neuromuscular blockers, sedatives, and thrombolytics to reflect distinct clinical protocols and supply pathways. Based on administration routes, performance and adoption vary across inhalation, intravenous, and oral delivery, each carrying different regulatory, storage, and administration implications that influence procurement and bedside workflows.

Patient demographics create differentiated demand profiles: adult patients, geriatric patients, neonatal intensive care patients, and pediatric patients each present unique physiological considerations, dosing challenges, and device sizing requirements that shape product development and procurement specifications. Therapeutic application segmentation highlights where specialty capabilities concentrate, spanning cardiovascular care, emergency resuscitation, neurological disorders, renal replacement therapy, and respiratory care; neurological disorders are parsed into intracranial pressure monitoring and traumatic brain injury, while respiratory care subdivides into asthma, chronic obstructive pulmonary disease, and pulmonary edema to reflect distinct clinical pathways. Finally, the end-user segmentation-ambulatory surgical centers, home healthcare, hospitals, and long-term care facilities-defines differences in purchasing cycles, capital budgets, and staff competencies, all of which influence adoption velocity and lifecycle support expectations.

Integrating these segmentation axes reveals high-priority intersections: for example, monitoring devices paired with geriatric patients in hospital settings demand interoperability and geriatric-specific algorithms, whereas intravenous infusion bags and neuromuscular blockers used in emergency resuscitation require streamlined logistics and rapid availability. The segmentation-driven view underscores the need for tailored go-to-market strategies that align product design, regulatory planning, and commercialization with the operational realities of each clinical niche.

Regional strategic dynamics that determine clinical adoption, regulatory access, and supply chain resilience across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape clinical adoption, regulatory timelines, and supplier footprints across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct advantages and constraints for manufacturers and providers. In the Americas, established reimbursement pathways and consolidated hospital systems create a fertile environment for evidence-based technologies that demonstrably reduce length of stay and complications, but the same markets also impose rigorous procurement scrutiny and competitive tendering that favor validated clinical outcomes.

Europe, Middle East & Africa presents a heterogeneous regulatory and payer landscape where national-level reimbursement policies and varied purchasing consortiums influence entry strategy; in many jurisdictions, regional procurement frameworks and public tendering demand extensive documentation of comparative effectiveness and lifecycle costs. In the Asia-Pacific region, rapid capacity expansion, growing investment in critical care infrastructure, and supplier ecosystems that span mature and emerging manufacturing hubs create opportunities for cost-competitive innovation, though regulatory harmonization remains a work in progress. Across these geographies, lead-time considerations, localization of service networks, and regulatory alignment are the primary determinants of commercial success, and organizations that invest in regional clinical evidence generation and localized supply chain resilience will see superior adoption outcomes.

Competitive behaviors and strategic imperatives among market leaders that combine product integration, evidence generation, and supply chain fortification

Competitive dynamics among leading firms reflect a dual imperative: sustain operational resilience while accelerating clinical differentiation. Companies that secure durable advantage have focused investments on integrated solutions that pair devices with analytics, robust post-market surveillance, and consumable ecosystems that lock in recurring revenue. Many leaders pursue modular platform strategies that allow incremental upgrades without wholesale replacement, reducing friction for hospital capital planners and enabling smoother clinical transitions.

Strategic partnerships have proliferated between device manufacturers, software integrators, and specialty pharmaceutical suppliers to enable bundled value propositions that address both clinical outcomes and cost-of-care metrics. Meanwhile, vertical integration-especially around sterilization, component supply, and regional manufacturing-reduces exposure to cross-border tariff and transportation shocks. Talent acquisition around regulatory affairs, health economics, and clinical evidence generation has become central to sustaining market access, as payers and procurement teams increasingly demand rigorous real-world performance data. Companies that balance rapid product iteration with disciplined post-market validation and regional service networks are better positioned to retain customer relationships and expand into adjacent therapeutic applications.

Prioritized practical actions that industry leaders can implement to strengthen supply chain resilience, clinical adoption, and evidence-driven differentiation

Industry leaders should prioritize a set of high-impact actions that translate insight into measurable improvements in availability, clinical performance, and commercial traction. First, align product roadmaps with clinical workflows by investing in interoperability standards and clinician-centered design; this reduces adoption friction and increases the probability that new monitoring and ventilation technologies become standard of care. Second, diversify manufacturing and supplier bases to mitigate tariff exposure and logistics disruptions, incorporating nearshoring and multi-sourcing clauses into procurement contracts to preserve continuity during geopolitical or trade shifts.

Third, accelerate robust real-world evidence generation through coordinated post-market studies and registry participation, coupling clinical endpoints with economic outcomes to support procurement negotiations and payer discussions. Fourth, develop tiered commercial models that reflect the differentiated needs of hospitals, ambulatory surgical centers, home healthcare, and long-term care facilities, enabling teams to tailor pricing, support, and training to end-user capabilities. Finally, invest in workforce capability building-clinical education, maintenance training, and digital literacy-to ensure technology deployments translate into better patient outcomes and strengthened customer loyalty. Executing these actions in sequence and in parallel will create resilient adoption pathways and durable competitive edges.

A transparent, triangulated research methodology combining primary clinical interviews, systematic secondary validation, and scenario testing to support strategic decisions

The research approach employed for this analysis combines structured primary inquiry with systematic secondary validation to ensure conclusions are evidence-based and operationally relevant. Primary research included targeted interviews with clinical leaders, procurement officers, and supply chain executives across acute care settings, enabling the capture of frontline perspectives on device usability, therapeutic selection, and inventory management practices. These qualitative insights were triangulated with product lifecycle documentation, regulatory filings, and publicly available clinical study reports to validate adoption drivers and risk vectors.

Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, and non-proprietary industry publications to contextualize clinical trends and technological trajectories. A rigorous triangulation framework reconciled disparate data points, while methodological safeguards-such as cross-respondent validation, temporal sensitivity checks, and provenance tracking-ensured robust inference. Where relevant, scenario testing assessed operational implications of supply disruptions and policy shifts, and sensitivity analysis informed recommendations related to sourcing and evidence generation. The methodology prioritizes transparency, reproducibility, and relevance to strategic decision-making within clinical and commercial teams.

A strategic conclusion emphasizing interoperability, sourcing resilience, and evidence programs as the pathway to improved outcomes and durable competitive advantage

In conclusion, critical care therapeutics are undergoing structural evolution driven by clinical innovation, procurement discipline, and heightened geopolitical sensitivity. The combined pressures of demands for better outcomes, tighter procurement scrutiny, and policy-driven trade disruptions require organizations to adapt across product design, supply chain architecture, and evidence generation. Those that integrate clinical workflow compatibility with resilient sourcing and focused real-world validation will unlock adoption pathways and create defensible market positions.

The strategic imperative for stakeholders is clear: prioritize interoperability and clinician usability, diversify supplier footprints to mitigate tariff and logistics risk, and construct evidence programs that link clinical outcomes to economic value. By doing so, manufacturers and providers can improve patient outcomes while insulating operations against the volatility of global trade and regulatory change. The insights and recommendations presented here provide a practical blueprint for translating current industry dynamics into durable competitive advantage and improved care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Critical Care Therapeutics Market, by Product Type

  • 8.1. Implantable Devices
  • 8.2. Intravenous Infusion Bags
  • 8.3. Medications
    • 8.3.1. Antibiotics
    • 8.3.2. Neuromuscular Blockers
    • 8.3.3. Sedatives
    • 8.3.4. Thrombolytics
  • 8.4. Monitoring Devices
  • 8.5. Syringes & Catheters
  • 8.6. Ventilators

9. Critical Care Therapeutics Market, by Administration Routes

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Critical Care Therapeutics Market, by Patient Demographics

  • 10.1. Adult Patients
  • 10.2. Geriatric Patients
  • 10.3. Neonatal Intensive Care Patients (NICU)
  • 10.4. Pediatric Patients

11. Critical Care Therapeutics Market, by Therapeutic Application

  • 11.1. Cardiovascular Care
  • 11.2. Emergency Resuscitation
  • 11.3. Neurological Disorders
    • 11.3.1. Intracranial Pressure Monitoring
    • 11.3.2. Traumatic Brain Injury
  • 11.4. Renal Replacement Therapy
  • 11.5. Respiratory Care
    • 11.5.1. Asthma
    • 11.5.2. Chronic Obstructive Pulmonary Disease
    • 11.5.3. Pulmonary Edema

12. Critical Care Therapeutics Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Healthcare
  • 12.3. Hospitals
  • 12.4. Long-Term Care Facilities

13. Critical Care Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Critical Care Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Critical Care Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Critical Care Therapeutics Market

17. China Critical Care Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Abeona Therapeutics Inc.
  • 18.7. ADMA Biologics, Inc.
  • 18.8. Albumedix Ltd. by Sartorius AG
  • 18.9. Aspen Group
  • 18.10. Bayer AG
  • 18.11. Becton, Dickinson and Company
  • 18.12. Bio Products Laboratory Ltd.
  • 18.13. Collegium Pharmaceutical, Inc.
  • 18.14. CSL Limited
  • 18.15. Eli Lilly and Company
  • 18.16. Gilead Sciences, Inc.
  • 18.17. GlaxoSmithKline plc
  • 18.18. Grifols SA
  • 18.19. Johnson & Johnson
  • 18.20. Kedrion Spa
  • 18.21. Merck & Co., Inc.
  • 18.22. Novartis AG
  • 18.23. Octapharma AG
  • 18.24. Pfizer Inc.
  • 18.25. Roche Holding AG
  • 18.26. Sanofi S.A.
  • 18.27. Shanghai RAAS
  • 18.28. Siemens Healthineers AG
  • 18.29. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEONATAL INTENSIVE CARE PATIENTS (NICU), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEONATAL INTENSIVE CARE PATIENTS (NICU), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEONATAL INTENSIVE CARE PATIENTS (NICU), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)